EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effect of Blonanserin on Neurotrophic Factors in Patients With Non‐Responsive First‐Episode Schizophrenia Treated With Early Risperidone Monotherapy—A Randomized Controlled Trial

Yaxue Wei iD, Yanting Liu, Lili Cai, Jinmian Li, Dandan Zheng, Huangde Fu, Shikai Wang, Guangbiao Huang

International Journal of Methods in Psychiatric Research · 2026-12 · 35 (4)

DOI: 10.1002/mpr.70111 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Methods in Psychiatric Research, online erschienen am 30.10.2026. Verfasst von Yaxue Wei und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology (Morita Ward), Fifth People's Hospital of Nanning, Mental Health Center Affiliated to Guangxi Medical University, Nanning, C…. Hauptthemen laut MEDLINE: Risperidone, Brain-Derived Neurotrophic Factor, Antipsychotic Agents, Phosphopyruvate Hydratase. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Huzhou Municipal Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the efficacy of Blonanserin in patients with schizophrenia who were refractory to Risperidone monotherapy and its effects on various neurotrophic factors.

Methods

A total of 120 patients with first‐episode schizophrenia who were hospitalized in our hospital from January 2022 to December 2023 and did not respond to early Risperidone monotherapy were selected as the study participants. They were randomly divided into a control group and a research group, with 60 cases in each group. The control group was treated with Clozapine, and the research group was treated with Blonanserin for 3 months. The scores of the Positive and Negative Syndrome Scale (PANSS), the scores of the Generic Quality of Life Inventory (GQOLI‐74), the serum brain‐derived neurotrophic factor (BDNF), the serum S100β protein, the neuron‐specific enolase (NSE), and the Neuregulin‐1 (NRG1) levels of the two groups were compared, and the adverse drug reactions of patients were recorded.

Results

After 3 months of treatment, the PANSS scores of both groups decreased compared with those before treatment, and the PANSS scores of the research group were lower. The scores of physical function, social function, and psychological function of the two groups were higher than those before treatment, and the scores of the research group were higher than those of the control group. The differences were statistically significant ( p < 0.05 for all). The serum BDNF and NRG1 levels of the two groups were higher than those before treatment, and those of the research group were higher than those of the control group. The S100β and NSE levels of the two groups were lower than those before treatment, and those of the research group were lower than those of the control group. The differences were statistically significant ( p < 0.05 for all). No serious adverse reactions occurred in both groups. Most patients with adverse reactions could tolerate them or improved after symptomatic treatment.

Conclusion

Blonanserin can effectively relieve the symptoms of schizophrenia and improve the quality of life of first‐episode schizophrenia patients who have failed to respond to Risperidone monotherapy in the early stage. Due to the short follow‐up time and small sample size of this study, further prospective multicenter studies should be carried out in the future to observe the long‐term treatment effect and provide more favorable reference for clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RisperidoneBrain-Derived Neurotrophic FactorAntipsychotic AgentsPhosphopyruvate HydratasePiperidinesPiperazinesS100 Calcium Binding Protein beta SubunitSchizophrenia, Treatment-ResistantSchizophreniaOutcome Assessment, Health CareNeuregulin-1Nerve Growth FactorsHumansFemaleMaleAdultYoung AdultAdolescentClozapine

Stichwörter der Autor:innen

blonanserinneurotrophic factorrisperidoneschizophrenia

Substanzen

blonanserinRisperidoneBrain-Derived Neurotrophic FactorAntipsychotic AgentsPhosphopyruvate HydratasePiperidinesPiperazinesS100 Calcium Binding Protein beta SubunitBDNF protein, humanNeuregulin-1

Autor:innen und Institutionen

  • Department of Psychology (Morita Ward), Fifth People's Hospital of Nanning, Mental Health Center Affiliated to Guangxi Medical University, Nanning, China.
  • Department of Children and Adolescents Psychological Ward, Fifth People's Hospital of Nanning, Mental Health Center Affiliated to Guangxi Medical University, Nanning, China.
  • Department of Psychiatry, Huzhou Third Municipal Hospital, The Affiliated Hospital of Huzhou University, Huzhou, China.
  • Department of Administrative Office, Fifth People's Hospital of Nanning, Mental Health Center Affiliated to Guangxi Medical University, Nanning, China.
  • Department of Psychiatry, Institute of Adolescents' Mental Health, Clinical Research Center for Children's Mental Health and Illness, Children's Hospital of Soochow University, Suzhou, China.

ORCID-Profile: Yaxue Wei

Förderung

  • Huzhou Municipal Science and Technology Bureau

Zitieren

APA

Wei, Y., Liu, Y., Cai, L., Li, J., Zheng, D., Fu, H., Wang, S., & Huang, G. (2026). Effect of Blonanserin on Neurotrophic Factors in Patients With Non‐Responsive First‐Episode Schizophrenia Treated With Early Risperidone Monotherapy—A Randomized Controlled Trial. International Journal of Methods in Psychiatric Research, 35(4). https://doi.org/10.1002/mpr.70111

Vancouver

Wei Y, Liu Y, Cai L, Li J, Zheng D, Fu H, et al. Effect of Blonanserin on Neurotrophic Factors in Patients With Non‐Responsive First‐Episode Schizophrenia Treated With Early Risperidone Monotherapy—A Randomized Controlled Trial. International Journal of Methods in Psychiatric Research. 2026;35(4). doi:10.1002/mpr.70111

BibTeX
@article{Wei2026,
  author = {Wei, Yaxue and Liu, Yanting and Cai, Lili and Li, Jinmian and Zheng, Dandan and Fu, Huangde and Wang, Shikai and Huang, Guangbiao},
  title = {Effect of Blonanserin on Neurotrophic Factors in Patients With Non‐Responsive First‐Episode Schizophrenia Treated With Early Risperidone Monotherapy—A Randomized Controlled Trial},
  journal = {International Journal of Methods in Psychiatric Research},
  year = {2026},
  volume = {35},
  number = {4},
  doi = {10.1002/mpr.70111}
}
Kostenlos starten →